IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

Go back to IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked
(NASDAQ: ICCM) Delayed: 5.93 +0.53 (9.81%)
Previous Close $5.40    52 Week High
Open $7.06    52 Week Low
Day High $7.53    P/E N/A 
Day Low $5.61    EPS
Volume 15,876,446